WAVE Life Sciences Ltd. (NASDAQ:WVE) Shares Bought by Moody Aldrich Partners LLC

Moody Aldrich Partners LLC lifted its holdings in shares of WAVE Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 10.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 439,827 shares of the company's stock after purchasing an additional 41,352 shares during the quarter. Moody Aldrich Partners LLC owned about 0.29% of WAVE Life Sciences worth $3,554,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of WVE. GF Fund Management CO. LTD. purchased a new position in WAVE Life Sciences during the 4th quarter valued at about $40,000. Quarry LP purchased a new position in WAVE Life Sciences during the 4th quarter valued at about $62,000. Summit Investment Advisors Inc. boosted its holdings in WAVE Life Sciences by 31.5% during the 4th quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company's stock valued at $119,000 after acquiring an additional 2,308 shares during the period. Westwood Wealth Management purchased a new position in WAVE Life Sciences during the 4th quarter valued at about $124,000. Finally, Ameriprise Financial Inc. purchased a new position in WAVE Life Sciences during the 4th quarter valued at about $129,000. 89.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Cantor Fitzgerald assumed coverage on WAVE Life Sciences in a research report on Tuesday, April 29th. They issued an "overweight" rating and a $10.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $22.00 price target on shares of WAVE Life Sciences in a research report on Wednesday, March 26th. Wall Street Zen lowered WAVE Life Sciences from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Raymond James Financial assumed coverage on WAVE Life Sciences in a research report on Wednesday, June 11th. They issued an "outperform" rating and a $14.00 price target on the stock. Finally, Wedbush reaffirmed an "outperform" rating and issued a $18.00 price target on shares of WAVE Life Sciences in a research report on Monday, June 23rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $20.50.

Insider Activity

In other WAVE Life Sciences news, Director Gregory L. Verdine sold 30,000 shares of the firm's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $6.95, for a total transaction of $208,500.00. Following the sale, the director directly owned 282,517 shares of the company's stock, valued at $1,963,493.15. This trade represents a 9.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 23.98% of the stock is owned by corporate insiders.

WAVE Life Sciences Stock Performance

NASDAQ WVE traded up $0.11 during trading hours on Monday, reaching $7.06. The company's stock had a trading volume of 1,401,542 shares, compared to its average volume of 1,283,924. The stock has a market cap of $1.10 billion, a PE ratio of -8.40 and a beta of -1.01. WAVE Life Sciences Ltd. has a fifty-two week low of $5.04 and a fifty-two week high of $16.74. The company's 50-day moving average is $6.72 and its two-hundred day moving average is $8.91.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.02). The company had revenue of $9.18 million for the quarter, compared to analysts' expectations of $11.65 million. During the same quarter last year, the firm posted ($0.24) earnings per share. Equities analysts expect that WAVE Life Sciences Ltd. will post -1.14 earnings per share for the current fiscal year.

About WAVE Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.